Ignite Creation Date:
2024-05-06 @ 3:31 AM
Last Modification Date:
2024-10-26 @ 11:34 AM
Study NCT ID:
NCT02302742
Status:
RECRUITING
Last Update Posted:
2023-05-09
First Post:
2014-11-11
Brief Title:
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
Sponsor:
University of Kansas Medical Center
Organization:
University of Kansas Medical Center
Study Overview
Official Title:
PROspective Evaluation of GErmline Mutations Cancer Outcome and Tissue Biomarkers A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PROGECT
Brief Summary:
PROGECT is a registry for patients with Triple Negative breast cancer TNBC or patients who have an identified germline mutations such as a mutation on the BRCA1 or BRCA2 genes
Detailed Description:
This study is being done to collect cancer-related information from patients with triple negative breast cancer and patients with hereditary genetic mutations This information will help us better understand the link between genetic changes and cancer outcome in patients with triple negative breast cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None